Positive Phase 3 results from both trials will seal FDA approval and immediately drive the stock price up to between $15 - $20 before FDA approval. I expect after positive Phase 3 results are announced and the stock hits between $15 - $20, Alfred Mann will invite big pharmaceutical company's interested in buying Mannkind to enter an auction process to buyout Mannkind and he will establish certain buyout criteria along with a minimum bidding price which I expect will mirror the then current price to be between $15 - $20. The auction should attract many big pharmaceutical company's who will make initial bids and there could be 3 to 4 rounds of bidding before one company wins out. Even after the auction is complete, Alfred Mann will leave room to negotiate with the winning company to increase the buyout price above the final auction bid price. I expect the criteria Alfred Mann will be looking for in the buyout is securing a fair buyout price for his shareholders, getting a company who has no conflict of interest and will aggressively commercialize Afrezza globally and lastly pick a company that agrees to keep Mannkind Inc.whole as company, as a subsidiary, to allow Mannkind to continue focusing on its core competencies. JMO but final buyout price could be between $30 - $35.
Ps. in addition to a fair price for his shareholders, when Al eventually sells, he will be looking to maximize the return on HIS investment (money, work, vision, innovation etc.) first and foremost. These returns will continue to build on his legacy (all his charitable activities) long after he is gone.
Sentiment: Strong Buy
hey Kev... agree with your numbers but if you are thinking that b/o price then i'm guessing you think that will happen next year some time after FDA approval.. cause personally I think they will get alot more than 30-35 bucks if we are talking 2016/2017 with 2 years of sales under their belt. opinion?